Bio-Rad Laboratories, Inc. announced its fourth-quarter and full-year 2025 financial results, reporting a 3.9% increase in total net sales to $693.2 million for Q4 2025 compared to Q4 2024. Despite this revenue growth, the company experienced a decline in GAAP gross margin to 49.8% and a significant GAAP operating loss of $118.9 million. Net income, however, saw a substantial increase to $720.0 million, largely due to a change in the fair market value of its investment in Sartorius AG.

Bio-Rad Laboratories reported a modest revenue increase of 0.5% to $653.0 million in Q3 2025 compared to the previous year. The company experienced a GAAP net loss of $341.9 million, primarily due to a change in the fair market value of its investment in Sartorius AG, but achieved a non-GAAP net income of $60.8 million. Operating margin improved, reflecting disciplined cost management.

Bio-Rad Laboratories delivered solid second-quarter 2025 results, with total net sales reaching $651.6 million, a 2.1% increase year-over-year. The company reported a net income of $317.8 million, a substantial turnaround from a net loss in the prior year, primarily driven by a favorable change in the fair market value of its investment in Sartorius AG. Non-GAAP diluted EPS was $2.61.

Bio-Rad reported a challenging first quarter for 2025 with a decrease in total net sales compared to the prior year. Despite the revenue decline, the company delivered solid margins through focused execution and careful expense management. The Life Science segment saw reduced sales primarily due to challenges in the academic research market, while the Clinical Diagnostics segment experienced a slight decrease mainly from lower diabetes testing reimbursements in China, offset by quality control product demand. Net income was significantly lower year-over-year due to a smaller gain from the change in fair market value of its Sartorius AG investment in Q1 2025 compared to Q1 2024.

Bio-Rad's Q4 2024 revenue decreased by 2.00% YoY to $667,500,000, impacted by a decline in the Life Science segment. However, Clinical Diagnostics grew slightly. Operating margin declined due to higher restructuring costs, but cost efficiencies helped maintain profitability.

Bio-Rad Laboratories reported a 2.8% increase in total net sales for Q3 2024, reaching $649.7 million. The company's net income significantly increased to $653.2 million, or $23.34 per share, driven by a change in the fair market value of its investment in Sartorius AG. Clinical Diagnostics segment sales increased, offsetting a slight decrease in Life Science segment sales.

Bio-Rad Laboratories reported second-quarter 2024 results with total net sales of $638.5 million, a decrease of 6.3% compared to the previous year. Despite revenue decline, the gross margin increased to 55.6% and operating income rose to $101.5 million. The company experienced a significant net loss of $2,165.5 million due to a change in the fair market value of its investment in Sartorius AG.

Bio-Rad's first quarter results were largely in line with expectations, with total net sales decreasing by 9.8 percent compared to the same period in 2023. The life science segment was impacted by ongoing weakness in the biotech and biopharma markets, while increased demand for clinical diagnostics products drove year-over-year growth for this business.

Bio-Rad's Q4 2023 results reflect a decrease in total net sales and income from operations compared to Q4 2022, primarily due to the ongoing weakness in biopharma markets and reduced COVID-related sales. While the Clinical Diagnostics segment saw growth, the Life Science segment experienced a decline. The company's net income was significantly impacted by changes in the fair market value of equity securities.

Bio-Rad Laboratories reported a decrease in total net sales for the third quarter of 2023, with $632.1 million compared to $680.8 million in the same period of 2022. The company's performance was below expectations due to reduced customer spending and macroeconomic challenges. The company is lowering its full-year 2023 outlook but remains confident about its overall strategy framework and long-term market opportunities.

Bio-Rad Laboratories reported a slight decrease in net sales for the second quarter of 2023, with a decline of 1.4 percent compared to the same period in 2022. The Life Science segment experienced a decrease in sales, while the Clinical Diagnostics segment saw an increase. The company is updating its financial outlook for the full year 2023, expecting non-GAAP currency-neutral revenue growth of approximately 0.8 percent.

Bio-Rad Laboratories reported a decrease in first-quarter 2023 net sales by 3.3% compared to the same period in 2022, with COVID-related sales significantly impacting the results. Excluding COVID-related sales, revenue increased by 6.1% on a currency neutral basis. The company is updating its financial outlook for full-year 2023 and full-year 2025.

Bio-Rad Laboratories reported a slight decrease in net sales for Q4 2022, with growth in the Life Science segment offset by a decline in the Clinical Diagnostics segment. The company saw a significant increase in net income compared to the previous year, primarily due to changes in the fair market value of equity securities.

Bio-Rad Laboratories reported a decrease in net sales for Q3 2022, with a significant drop in COVID-related revenue. While core product demand remained strong, supply chain constraints affected instrument placements. The company is focusing on reducing backlog and advancing strategic activities for the remainder of the year.

Bio-Rad Laboratories reported a decrease in net sales for the second quarter of 2022, with a net loss primarily impacted by changes in the fair market value of equity securities. However, the company anticipates non-GAAP currency-neutral revenue growth to be at the high end of the prior guidance.

Bio-Rad Laboratories reported a decrease in first-quarter net sales by 3.7% compared to the previous year, with sales totaling $700.1 million. The decline was partially attributed to lower COVID-19 related revenue, though excluding these sales, revenue increased by 6.5% on a currency-neutral basis. The company's Life Science segment experienced a decrease in sales, while the Clinical Diagnostics segment saw a slight increase. Despite a net loss of $3,369.6 million, the underlying strength of the core business is encouraging.

Bio-Rad reported Q4 2021 net sales of $732.8 million, a 7.2% decrease compared to Q4 2020. The company experienced a net loss of $1,573.7 million, or $52.59 per share, compared to a net income of $839.1 million, or $27.81 per share in the same period last year. COVID-related revenue was approximately $46 million, versus $132 million in 2020.

Bio-Rad Laboratories reported a 15.4% increase in net sales for the third quarter of 2021, reaching $747.0 million compared to $647.3 million in the same period of 2020. The company's income from operations rose to $156.8 million, and net income reached $3,928.0 million, or $129.96 per share. Non-GAAP net income was $112.2 million, or $3.71 per share.

Bio-Rad Laboratories reported a strong second quarter in 2021, with net sales increasing by 33.4% to $715.9 million compared to the same period in 2020. The company's Life Science and Clinical Diagnostics segments both performed well, and the company has updated its full-year guidance to reflect this performance.

Bio-Rad Laboratories reported a significant increase in first-quarter net sales, driven by growth in both the Life Science and Clinical Diagnostics segments. Net sales increased by 27.1% compared to the same period in 2020, with a notable contribution from products supporting COVID-19 research and testing. The company's profitability also improved, with a higher operating margin and net income.

Bio-Rad reported a strong Q4 2020 with a 26.5% increase in net sales compared to Q4 2019. The growth was largely driven by high demand for COVID-19 related products and a damages award. The company's Life Science segment experienced substantial growth, while the Clinical Diagnostics segment saw a decrease in sales.

Bio-Rad Laboratories reported a strong third quarter with a 15.5% increase in net sales to $647.3 million. The Life Science segment saw significant growth driven by PCR product lines, while the Clinical Diagnostics segment experienced a decline. Net income was $1,314.8 million, or $43.64 per share, compared to a net loss in the same period last year.

Bio-Rad Laboratories reported a decrease in second-quarter net sales by 6.2% compared to the previous year, while net income increased significantly due to the recognition of changes in the fair market value of equity securities. The COVID-19 pandemic had both positive and negative impacts on the company's business operations. The company is not providing annual guidance due to the uncertainty.

Bio-Rad reported a 3.2% increase in net sales for Q1 2020 compared to Q1 2019, with significant impacts from changes in the fair market value of equity securities. The company is withdrawing its previously issued annual guidance due to uncertainties related to the COVID-19 pandemic.

Bio-Rad Laboratories reported Q4 2019 net sales of $624.4 million, a 1.2% increase year-over-year. Net income for the quarter was $553.5 million, or $18.31 per share, compared to a net loss in Q4 2018. The company experienced a cyberattack during the quarter that impacted sales and operations.